Amylyx Stock Analysis

AMLX
 Stock
  

USD 30.19  2.04  7.25%   

The current price rise of Amylyx Pharmaceuticals could raise concerns from investors as the firm is trading at a share price of 30.19 on 1,186,533 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in November. The stock standard deviation of daily returns for 90 days investing horizon is currently 8.09. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Amylyx Pharmaceuticals partners.
Please continue to Trending Equities.
  
The Amylyx Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Amylyx Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Amylyx Stock analysis module also helps to analyze the Amylyx Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Amylyx Stock Analysis Notes

About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 6.76. Amylyx Pharmaceuticals last dividend was issued on the 28th of March 1970. Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Amylyx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 205 people. For more info on Amylyx Pharmaceuticals please contact the company at 617 682 0917 or go to https://amylyx.com.

Amylyx Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Amylyx Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Amylyx Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Amylyx Pharmaceuticals is way too risky over 90 days horizon
Amylyx Pharmaceuticals appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 285 K. Net Loss for the year was (121.26 M) with loss before overhead, payroll, taxes, and interest of (43.76 M).
Amylyx Pharmaceuticals currently holds about 255.2 M in cash with (102.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.36.
Roughly 30.0% of the company shares are held by company insiders
Latest headline from www.marketscreener.com: Amylyx Shares Rally Premarket on FDA Approval of ALS Drug - Marketscreener.com

Amylyx Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Amylyx Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Amylyx Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Amylyx Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
9th of September 2022
Unclassified Corporate Event
View
11th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of July 2022
Financial Statements and Exhibits. Other Events
View
21st of June 2022
Unclassified Corporate Event
View
13th of June 2022
Financial Statements and Exhibits. Other Events
View
9th of June 2022
Submission of Matters to a Vote of Security Holders
View
3rd of June 2022
Financial Statements and Exhibits. Other Events
View
12th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Amylyx Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Amylyx Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Amylyx Pharmaceuticals backward and forwards among themselves. Amylyx Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Amylyx Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Viking Global Investors LpCommon Shares7.2 M138.1 M
Perceptive Advisors LlcCommon Shares3.5 M68.2 M
Boxer Capital LlcCommon Shares2.2 M42.4 M
Bain Capital Life Sciences Investors LlcCommon Shares1.9 M37.5 M
Vanguard Group IncCommon Shares994 K19.1 M
Rock Springs Capital Management LpCommon Shares974.1 K18.8 M
Verition Fund Management LlcCommon Shares950.1 K18.3 M
Ikarian Capital LlcCall Options350.8 K6.8 M
Note, although Amylyx Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Amylyx Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.52 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amylyx Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Amylyx Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (86.34) % which means that it has lost $86.34 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (188.05) %, meaning that it created substantial loss on money invested by shareholders. Amylyx Pharmaceuticals management efficiency ratios could be used to measure how well amylyx pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 2nd of October, Amylyx Pharmaceuticals shows the Risk Adjusted Performance of 0.1425, downside deviation of 5.75, and Mean Deviation of 4.32. Amylyx Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Amylyx Pharmaceuticals, which can be compared to its rivals. Please confirm Amylyx Pharmaceuticals jensen alpha and semi variance to decide if Amylyx Pharmaceuticals is priced correctly, providing market reflects its regular price of 28.15 per share. Given that Amylyx Pharmaceuticals has jensen alpha of 1.1, we suggest you to validate Amylyx Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Amylyx Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. Amylyx Pharmaceuticals Triple Exponential Moving Average indicator shows smoothing effect of Amylyx Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Amylyx Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amylyx Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amylyx Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amylyx Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viking Global Investors Lp over three weeks ago via Macroaxis 
Sale by Viking Global Investors Lp of 3142 shares of Amylyx Pharmaceuticals
Als Invest 1 Bv over two months ago via Macroaxis 
Sale by Als Invest 1 Bv of 2307 shares of Amylyx Pharmaceuticals
Quimi Daphne over three months ago via Macroaxis 
Acquisition by Quimi Daphne of 19000 shares of Amylyx Pharmaceuticals subject to Rule 16b-3
Cheng Isaac over three months ago via Macroaxis 
Acquisition by Cheng Isaac of 19000 shares of Amylyx Pharmaceuticals subject to Rule 16b-3
Cohen Joshua B over three months ago via Macroaxis 
Exercise or conversion by Cohen Joshua B of 334520 shares of Amylyx Pharmaceuticals subject to Rule 16b-3
Als Invest 1 Bv over three months ago via Macroaxis 
Conversion by Als Invest 1 Bv of 4826503 shares of Amylyx Pharmaceuticals
Morningside Venture Investments Ltd over six months ago via Macroaxis 
Conversion by Morningside Venture Investments Ltd of 1621544 shares of Amylyx Pharmaceuticals
Mazzariello Gina over six months ago via Macroaxis 
Acquisition by Mazzariello Gina of 182000 shares of Amylyx Pharmaceuticals subject to Rule 16b-3
Morningside Venture Investments Ltd over six months ago via Macroaxis 
Conversion by Morningside Venture Investments Ltd of 1621544 shares of Amylyx Pharmaceuticals
Dragsa 96 Llc over six months ago via Macroaxis 
Amylyx Pharmaceuticals exotic insider transaction detected
Viking Global Investors Lp over six months ago via Macroaxis 
Amylyx Pharmaceuticals exotic insider transaction detected
Olinger Margaret over six months ago via Macroaxis 
Acquisition by Olinger Margaret of 127500 shares of Amylyx Pharmaceuticals subject to Rule 16b-3

Amylyx Pharmaceuticals Predictive Daily Indicators

Amylyx Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Amylyx Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Amylyx Pharmaceuticals Forecast Models

Amylyx Pharmaceuticals time-series forecasting models is one of many Amylyx Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amylyx Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Amylyx Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Amylyx Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amylyx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Amylyx Pharmaceuticals. By using and applying Amylyx Stock analysis, traders can create a robust methodology for identifying Amylyx entry and exit points for their positions.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Amylyx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 205 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Amylyx Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module
Please continue to Trending Equities. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for analysis

When running Amylyx Pharmaceuticals price analysis, check to measure Amylyx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amylyx Pharmaceuticals is operating at the current time. Most of Amylyx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Amylyx Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Amylyx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Amylyx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Amylyx Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amylyx Pharmaceuticals. If investors know Amylyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amylyx Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amylyx Pharmaceuticals is measured differently than its book value, which is the value of Amylyx that is recorded on the company's balance sheet. Investors also form their own opinion of Amylyx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Amylyx Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amylyx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Amylyx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amylyx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Amylyx Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amylyx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.